文献速递白血病

儿童淋巴细胞白血病减低强度治疗:诱导早期残留病的影响

Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction.
PubMed 文献 · Blood · 2021-01-01

该研究纳入200例具有良好临床病理特征且第19天及诱导结束时骨髓流式MRD<0.01%的B前体ALL患儿,接受减低强度治疗。5年无事件生存率89.5%,总生存率95.5%,5年累积复发率7%。

要点

  • VLR ALL患儿采用低强度治疗可获得良好生存,5年EFS 89.5%、OS 95.5%。
  • 第19天MRD 0.001%至<0.01%者复发风险显著高于MRD不可测者。
  • 更敏感的MRD检测可能进一步细化VLR分类标准。

核心结论

  • VLR ALL患儿可成功接受减低强度治疗。
  • 第19天MRD在0.001%至<0.01%者5年累积复发率显著高于MRD不可测者。
  • 采用更敏感MRD检测可能进一步细化VLR分类标准。

研究设计与样本

  • 患儿具有良好临床病理特征,第19天及诱导结束时骨髓流式MRD<0.01%。
  • 所有患儿接受减低强度治疗。

主要发现

  • 5年无事件生存率89.5%(标准误2.2%)。
  • 5年总生存率95.5%(标准误1.5%)。
  • 5年累积复发率7%(95%CI 4-11%)。
  • 第19天MRD 0.001%至<0.01%者29例,5年累积复发率17.2%(标准误7.2%)。

关键数值与推荐

  • VLR入选标准:良好临床病理特征且第19天及诱导结束时骨髓流式MRD<0.01%。
  • 第19天MRD 0.001%至<0.01%者5年累积复发率17.2%±7.2%。
  • MRD不可测者5年累积复发率5.3%±1.7%。

临床怎么用

  • VLR ALL患儿可考虑减低强度治疗。
  • 第19天MRD在0.001%至<0.01%者应警惕较高复发风险。
  • 可探索更敏感MRD检测以优化VLR风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Legacy data show that ∼40% of children with acute lymphoblastic leukemia (ALL) were cured with limited antimetabolite-based chemotherapy regimens. However, identifying patients with very-low-risk (VLR) ALL remains imprecise. Patients selected based on a combination of presenting features and a minimal residual disease (MRD) level <0.01% on day 19 of induction therapy had excellent outcomes with low-intensity treatment. We investigated the impact of MRD levels between 0.001% and <0.01% early in remission induction on the outcome of VLR ALL treated with a low-intensity regimen. Between October of 2011 and September of 2015, 200 consecutive patients with B-precursor ALL with favorable clinicopathologic features and MRD levels <0.01%, as assessed by flow cytometry in the bone marrow on day 19 and at the end of induction therapy, received reduced-intensity therapy. The 5-year event-free survival was 89.5% (± 2.2% standard error [SE]), and the overall survival was 95.5% (± 1.5% SE). The 5-year cumulative incidence of relapse (CIR) was 7% (95% confidence interval, 4-11%). MRD levels were between 0.001% and <0.01% on day 19 in 29 patients. These patients had a 5-year CIR that was significantly higher than that of patients with undetectable residual leukemia (17.2% ± 7.2% vs 5.3% ± 1.7%, respectively; P = .02). Our study shows that children with VLR ALL can be treated successfully with decreased-intensity therapy, and it suggests that the classification criteria for VLR can be further refined by using a more sensitive MRD assay.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sidhom I, Shaaban K, Youssef SH, et al. Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction. Blood. 2021. PMID: 33410896. doi:10.1182/blood.2020007977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。